Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
aberrant, alpha, angular, Assoc, atrophy, attack, atypical, back, Bioreliance, Camille, Canadian, carcinogenicity, CGT, cleaning, context, cortical, cyber, David, depth, exemplified, favour, Finkelstein, forecast, frequency, HCI, highlighted, hippocampal, INCResearch, infrastructure, innate, intercede, JM, label, Larry, Laureate, lifespan, malware, mentioned, neurocognitive, organisation, parkinsonian, play, pro, rare, rata, reconcile, refiled, repeatable, Rockville, scan, shelf, SIC, sought, SPP, step, Sth, striatal, Supply, symposium, tangle, tau, tauopathy, underwritten, unsuccessful, update, veracity, volumetric
Removed:
achieving, acute, Andrea, assisting, attained, attestation, chronic, Columbia, confirmed, consummate, covering, cycle, de, dismissed, District, dosing, enhance, exclude, extend, extensively, formed, gift, Greece, Hahn, hour, hypothesize, impurity, intrinsic, Liberman, likelihood, lowered, markedly, member, neuroprotection, noncash, participation, perish, plasma, precursor, Precusor, Pub, recalculation, Reconciliation, reflecting, released, requested, rescue, SPV, Strike, structural, Swedish, today, ultimate, unblinded, unchanged, withdrawn
Filing tables
Filing exhibits
- 20-F Annual report (foreign)
- 4.9 Exhibit 4.9
- 4.15 Exhibit 4.15
- 4.24 Exhibit 4.24
- 4.25 Exhibit 4.25
- 4.26 Exhibit 4.26
- 4.27 Exhibit 4.27
- 4.28 Exhibit 4.28
- 4.29 Exhibit 4.29
- 4.30 Exhibit 4.30
- 4.31 Exhibit 4.31
- 8.1 Exhibit 8.1
- 12.1 Exhibit 12.1
- 12.2 Exhibit 12.2
- 13.1 Exhibit 13.1
- 13.2 Exhibit 13.2
- 15.1 Exhibit 15.1
ATHE similar filings
Filing view
External links
Exhibit 13.2
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Prana Biotechnology Limited (the “Company”) on Form 20-F for the period ended June 30, 2013, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Richard Revelins, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
/s/ Richard Revelins* Richard Revelins Chief Financial Officer |
October 22, 2013
* The originally executed copy of this Certification will be maintained at the Company’s offices and will be made available for inspection upon request.